Human PilotPubMed ID: 33877333·2021

Semaglutide Improves Hepatic Fibrosis in Non-Alcoholic Fatty Liver Disease

Newsome PN, Buchholtz K, Cusi K, et al.

New England Journal of Medicine, 2021 · n = 320

Key finding

Semaglutide 0.4mg reduced liver fat by 37% versus 10% placebo (p<0.001); 59% achieved ≥30% relative reduction in liver fat.

Summary

Phase 2b trial demonstrating semaglutide reduced liver fat content and improved fibrosis markers in NAFLD patients.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

SemaglutideL5

An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management.

More research on Semaglutide

Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity (SELECT)

New England Journal of Medicine · 2023 · Human RCT

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF)

New England Journal of Medicine · 2023 · Human RCT

Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5)

Nature Medicine · 2022 · Human RCT

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (STEP 8)

JAMA · 2022 · Human RCT

STEP 3: Semaglutide for Weight Management in Severe Obesity

New England Journal of Medicine · 2022 · Human RCT